Skip to search formSkip to main contentSkip to account menu
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
TLDR
Data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis.
View on Publisher
HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer
TLDR
Mir-193a-5p, HGF and c-Met expression may help select eligible patients for this modality of treatment, and inhibitors of this pathway may improve the efficacy of NACT.
View PDF
Anthelmintic resistance and homeostatic plasticity (Brugia malayi)
TLDR
Motility, calcium-imaging, patch-clamp and molecular experiments showed the muscle AChRs are dynamic with mechanisms that adjust their subtype composition and sensitivity to levamisole, which allows the parasite to adapt resisting the anthelmintic.
View on PubMed
Knockdown of phosphoethanolamine transmethylation enzymes decreases viability of Haemonchus contortus.
View on PubMed
Silencing of GRA10 protein expression inhibits Toxoplasma gondii intracellular growth and development.
View on PubMed
Herpes Virus MicroRNA Expression and Significance in Serous Ovarian Cancer
TLDR
Integrated analysis of gene and viral miRNAs expression suggests that miR-BART7 induces directly cisplatin-resistance, whilemiR-H25 alters RNA processing and affects the expression of noxious human mi RNAs such as miR -143.
View PDF
In vitro anthelmintic efficacy of inhibitors of phosphoethanolamine Methyltransferases in Haemonchus contortus
View on PubMed
Integrated Multidimensional Analysis Is Required for Accurate Prognostic Biomarkers in Colorectal Cancer
TLDR
Newly derived integrated biomarkers have the potential to meaningfully guide the selection of therapeutic strategies for individual patients while elucidating molecular mechanisms driving disease progression.
View PDF
Receptor Tyrosine Kinases Involved in Tumor Progression Activity and Targets the RAF/MEK/ERK Pathway and BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor
TLDR
Data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis.
Cholinergic receptors on intestine cells of Ascaris suum and activation of nAChRs by levamisole
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License